Short Interest in Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Grows By 360.0%

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,300 shares, an increase of 360.0% from the March 31st total of 500 shares. Based on an average trading volume of 4,600 shares, the short-interest ratio is presently 0.5 days.

Inhibitor Therapeutics Stock Performance

Shares of OTCMKTS:INTI remained flat at $0.09 during midday trading on Friday. Inhibitor Therapeutics has a 1 year low of $0.01 and a 1 year high of $0.30. The firm has a market cap of $14.76 million, a price-to-earnings ratio of -8.58 and a beta of -0.84. The firm has a 50-day moving average of $0.07 and a 200-day moving average of $0.08.

Inhibitor Therapeutics (OTCMKTS:INTI) last released its quarterly earnings results on Friday, March 29th. The company reported ($0.01) earnings per share (EPS) for the quarter.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.